Using a bioinformatics approach, researchers found that CD4+ T cell’s binding partner, a molecule called MHC-II, may have even more influence on emerging tumors than MHC-I, the better known partner of CD8+ T cells. The finding may help researchers improve cancer immunotherapies and predict which patients will respond best.